One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Aims+Scope/Editorial Board/Publication information
doi : 10.1016/S0167-8140(23)00318-3
Volume 185, August 2023, 109780
Introducing the ESTRO Guidelines Committee, the driving force for the new generation of ESTRO guidelines
Fiona McDonald a,b , Claus Belka c,d,e , Coen Hurkmans f , Barbara Alicja Jereczek-Fossa g,h , Philip Poortmans i,j , Jeroen B. van de Kamer k , Eralda Azizaj l , Pierfrancesco Franco
doi : 10.1016/j.radonc.2023.109724
Volume 185, August 2023, 109724
ESTRO-ACROP guideline: Recommendations on implementation of breath-hold techniques in radiotherapy
Marianne Camille Aznar a,?, Pablo carrasco de fez b , Stefanie Corradini c , Mirjam Mast d , Helen McNair e , Icro Meattini f,g , Gitte Persson h,i , Paul van Haaren
doi : 10.1016/j.radonc.2023.109734
Volume 185, August 2023, 109734
Randomized controlled study of pain education in patients receiving radiotherapy for painful bone metastases
Jenske I. Geerling a , Yvette M. van der Linden b,c , Natasja J.H. Raijmakers d , Karin M. Vermeulen e , Veronique E.M. Mul f , Ellen J.M. de Nijs c , Paulien G Westhoff g , Geertruida H. de Bock e , Alexander de Graeff h , Anna K.L. Reyners
doi : 10.1016/j.radonc.2023.109687
Volume 185, August 2023, 109687
From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: Primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial
Lisa De Cock a,1 , Cédric Draulans a,1,?, Floris J. Pos b , Sofie Isebaert a,c , Robin De Roover c , Uulke A. van der Heide b , Robert J. Smeenk d , Martina Kunze-Busch d , Jochem van der Voort van Zyp e , Hans de Boer e , Linda G.W. Kerkmeijer d,e , Karin Haustermans
doi : 10.1016/j.radonc.2023.109713
Volume 185, August 2023, 109713
Radiotherapy for Ledderhose disease: Results of the LedRad-study, a prospective multicentre randomised double-blind phase 3 trial☆
Anneke de Haan a,?, Johanna G.H. van Nes b , M. Willemijn Kolff c , Peter-Paul van der Toorn d , A. Helen Westenberg e , Annelies E. van der Vegt f,1 , Henk Groen g , Jelle Overbosch h , Hans Paul van der Laan a , Paul M.N. Werker i , Johannes A. Langendijk a , Roel J.H.M. Steenbakkers
doi : 10.1016/j.radonc.2023.109718
Volume 185, August 2023, 109718
AN0025, a novel antagonist of PGE2-receptor E-type 4 (EP4), in combination with total neoadjuvant treatment of advanced rectal cancer
Lucjan Wyrwicz a,?, Mark Saunders b , Marcia Hall c , John Ng d , Theodore Hong e , Sherry Xu f , Justin Lucas f , Xuyang Lu f , Nathan Lautermilch f , Silvia Formenti d , Robert Glynne-Jones c
doi : 10.1016/j.radonc.2023.109669
Volume 185, August 2023, 109669
Mapping the location of local and regional recurrences according to breast cancer surgery and radiation therapy: Results from EORTC 22922/10925
Orit Kaidar-Person a,b,c,?, Peggy Giasafaki d , Liesbeth Boersma c , Peter De Brouwer e , Caroline Weltens f , Carine Kirkove g , Karine Peignaux-Casasnovas h , Volker Budach i , Femke van der Leij j , Ernest Vonk k , Nicola Weidner l , Sofia Rivera m , Geertjan van Tienhoven n , Alain Fourquet o , Georges Noel p , Mariacarla Valli q , Matthias Guckenberger r , Eveline Koiter s , Severine Racadot t , Roxolyana Abdah-Bortnyak u , Harry Bartelink v , Henk Struikmans w , Catherine Fortpied d , Philip M. Poortmans x,y , for the EORTC Radiation Oncology and Breast Cancer Groups
doi : 10.1016/j.radonc.2023.109698
Volume 185, August 2023, 109698
Constructing an individualized surveillance framework for nasopharyngeal carcinoma based on a dynamic risk-adapted approach
Tianzhu Lu a,b,c,1 , Hanchuan Xu a,1 , Wanfang Huang a , Jingfeng Zong a , Caizhu Pan a , Chaobin Huang a , Youping Xiao d , Bijuan Chen a , Jingao Li b,c , Jianji Pan a,e , Shaojun Lin a,e , Fang Guo f,?, Qiaojuan Guo
doi : 10.1016/j.radonc.2023.109716
Volume 185, August 2023, 109716
Sinonasal mucosal melanoma: Is there a need for elective neck irradiation?
Shiran Sun a , Ye Zhang a , Xiaodong Huang a , Kai Wang a , Yuan Qu a , Runye Wu a , Xuesong Chen a , Jingbo Wang a , Jianghu Zhang a , Jingwei Luo a , Guozhen Xu a , Ye-Xiong Li a , Junlin Yi
doi : 10.1016/j.radonc.2023.109642
Volume 185, August 2023, 109642
Prognostic value of circulating Epstein-Barr virus DNA level post-induction chemotherapy for patients with nasopharyngeal carcinoma: A recursive partitioning risk stratification analysis
Fang-Fang Kong 1 , Guang-Sen Pan 1 , Cheng-Run Du 1 , Meng-Shan Ni, Rui-Ping Zhai, Xia-Yun He, Chun-Ying Shen, Xue-Guan Lu, Chao-Su Hu ?, Hong-Mei Ying ?
doi : 10.1016/j.radonc.2023.109721
Volume 185, August 2023, 109721
A competing risk analysis of the patterns and risk factors of recurrence in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy
Marion Tonneau a,b , Corentin Richard a , Bertrand Routy a , Marie-Pierre Campeau c , Toni Vu c , Edith Filion c , David Roberge c , Dominique Mathieu c , Robert Doucet c , Dominic Beliveau-Nadeau c , Houda Bahig a,c
doi : 10.1016/j.radonc.2023.109697
Volume 185, August 2023, 109697
Independent association of metabolic tumor response on FDG-PET with pulmonary toxicity following risk-adaptive chemoradiation for unresectable non-small cell lung cancer: Inherent radiosensitivity or immune response?
Evan D.H. Gates a , Daniel S. Hippe b , Hubert J. Vesselle c , Jing Zeng a , Stephen R. Bowen
doi : 10.1016/j.radonc.2023.109720
Volume 185, August 2023, 109720
Does coronary artery calcium score have an impact on overall survival for locally advanced non-small cell lung cancer treated with definitive radiotherapy
Agon Olloni a,b,c,?, Carsten Brink b,d , Ebbe L. Lorenzen b,d , Stefan S. Jeppesen a,b,c , Lone Hoffmann e,f , Charlotte Kristiansen g , Marianne M. Knap e , Ditte S. M?ller e , Lotte Nyg?rd h , Gitte F. Persson i,j , Rune S. Thing g , Hella MB. Sand k , Axel Diederichsen b,l , Tine Schytte
doi : 10.1016/j.radonc.2023.109719
Volume 185, August 2023, 109719
Pretreatment 18-FDG-PET/CT parameters can serve as prognostic imaging biomarkers in recurrent NSCLC patients treated with reirradiation-chemoimmunotherapy
Brane Grambozov a,?, Forough Kalantari b,c , Mohsen Beheshti c , Markus Stana a , Josef Karner a , Elvis Ruznic a , Barbara Zellinger d , Felix Sedlmayer a,e , Gabriel Rinnerthaler f,g , Franz Zehentmayr
doi : 10.1016/j.radonc.2023.109728
Volume 185, August 2023, 109728
Can radiation restore immunotherapy response in metastatic melanoma refractory to checkpoint inhibitors: An institutional experience in salvaging immunotherapy resistant disease
Mohannad Alhumaid a , Deepak Dinakaran a , Michael Smylie b , John Walker b , Kurian Joseph a,?
doi : /10.1016/j.radonc.2023.109712
Volume 185, August 2023, 109712
Prospective evaluation of in vivo and phantom repeatability and reproducibility of diffusion-weighted MRI sequences on 1.5Â T MRI-linear accelerator (MR-Linac) and MR simulator devices for head and neck cancers
Brigid A. McDonald a,?, Travis Salzillo a , Samuel Mulder a , Sara Ahmed a , Alex Dresner b , Kathryn Preston a , Renjie He a , John Christodouleas c , Abdallah S.R. Mohamed a , Marielle Philippens d , Petra van Houdt e , Daniela Thorwarth f , Jihong Wang a , Amita Shukla Dave g , Michael Boss h , Clifton D. Fuller
doi : 10.1016/j.radonc.2023.109717
Volume 185, August 2023, 109717
Serum miRNA-based signature indicates radiation exposure and dose in humans: A multicenter diagnostic biomarker study
Zuzanna Nowicka a , Bart?omiej Tomasik a,b,c , David Kozono b,d , Konrad Stawiski a , Thomas Johnson d , Daphne Haas-Kogan b , Marek Ussowicz e , Dipanjan Chowdhury b,?, Wojciech Fendler
doi : 10.1016/j.radonc.2023.109731
Volume 185, August 2023, 109731
Predicting the germline dependence of hematuria risk in prostate cancer radiotherapy patients
Jung Hun Oh a,?, Sangkyu Lee a , Maria Thor a , Barry S. Rosenstein b , Allen Tannenbaum c , Sarah Kerns d,1 , Joseph O. Deasy
doi : 10.1016/j.radonc.2023.109723
Volume 185, August 2023, 109723
A systematic analysis of the particle irradiation data ensemble in the key of the microdosimetric kinetic model: Should clonogenic data be used for clinical relative biological effectiveness?
Daniel Su?rez-Garc?a a , Miguel Antonio Cortés-Giraldo a , Alejandro Bertolet
doi : 10.1016/j.radonc.2023.109730
Volume 185, August 2023, 109730
18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial: Should dose intensification be discontinued or should accelerated schemes remain an important area of clinical research?
Fabio Arcidiacono Paola Anselmo ? Michelina Casale Fabio Trippa
doi : 10.1016/j.radonc.2023.109688
Volume 185, August 2023, 109688
In Response to Arcidiacono et al.: “Should dose intensification be discontinued or should accelerated schemes remain an important area of clinical research?�
Saskia A. Cooke ? Jan-Jakob Sonke José S.A. Belderbos
doi : 10.1016/j.radonc.2023.109690
Volume 185, August 2023, 109690
One size does not fit all: PMRT in ypN0 HER-2 positive breast cancer
Omran SaifiYoussef H. Zeidan
doi : 10.1016/j.radonc.2023.109725
Volume 185, August 2023, 109725
Having ypN0 may not be enough to abandon the Postmastectomy Radiotherapy (PMRT) in Her-2 positive patients
Merdan Fayda
doi : 10.1016/j.radonc.2023.109722
Volume 185, August 2023, 109722
